The US FDA on 6 November sanctioned pharma giant Pfizer's Xeljanz (tofacitinib citrate) as a treatment for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or are intolerant to methotrexate – granting the approval two weeks ahead of the medicine's action goal date.
The drug is the first Janus kinase (JAK) inhibitor approved for RA – only the second JAK inhibitor to gain...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
